Legal Opinion
Amgen, Inc. v. Ariad Pharmaceuticals, Inc.
District Court, D. Delaware
Decided March 27, 2007No. Civ. A. 06-259-MPTPublishedCited by 2 opinions
1Opinion of the Court
MEMORANDUM OPINION
THYNGE, United States Magistrate Judge.
I. Introduction
On April 20, 2006, Amgen Inc. and related entities (collectively “Amgen”) filed a declaratory judgment action asserting that each claim of U.S. Patent No. 6,410,516 (“ ’516 patent”) is invalid. The ’516 patent is owned by the Massachusetts Institute of Technology (“MIT”), the Whitehead Institute for Biomedical Research (‘Whitehead”), and the President and Fellows of Harvard College (“Harvard”) (collectively, “Institutions”). 1 ARIAD Pharmaceuticals, Inc. (“ARIAD”) is the exclusive licensee 2 of the ’516 patent and is the…
2Cases cited18 opinions
- George Jumara and Evangelina Jumara, H/w v. State Farm Insurance CompanyCourt of Appeals for the Third Circuit · 1995
- Independent Wireless Telegraph Co. v. Radio Corp. of AmericaSupreme Court of the United States · 1926
- Vaupel Textilmaschinen Kg and Vaupel North America v. Meccanica Euro Italia S.P.A. And American Trim Products, Inc., Defendants/cross-AppellantsCourt of Appeals for the Federal Circuit · 1991
- Field v. Volkswagenwerk AGCourt of Appeals for the Third Circuit · 1980
- Prima Tek II, L.L.C. v. A-Roo Co.Court of Appeals for the Federal Circuit · 2000
13 more not listed; retrieve them via the Exa API.
3Cited by2 opinions
- Mallinckrodt, Inc. v. EZ-EM INC.District Court, D. Delaware · 2009
- Retzlaff v. Horace Mann InsuranceDistrict Court, D. Delaware · 2010